LivaNova Announces OSPREY Study Meets Key Safety and Efficacy Endpoints
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, today announced that its OSPREY randomized controlled trial (RCT) met its primary safety and efficacy endpoints. The trial, which evaluated the LivaNova aura6000™ System for treating obstructive sleep apnea (OSA) using…
Hero Digital Wins Multiple eHealthcare Leadership Awards for Customer Experience
Hero Digital, a leading digital customer experience agency, has won several prestigious eHealthcare Leadership Awards for its outstanding work with UNC Health and Atlantic Health System. These awards recognize the most exceptional healthcare websites and digital initiatives, underscoring the crucial…
Neurogene Reports Positive Interim Data from NGN-401 Gene Therapy Trial for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases, today reported positive interim results from the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label clinical trial evaluating…
TriSalus Partners with Geo-Med to Expand TriNav® Access for U.S. Veterans with Liver Cancer
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology-focused company committed to improving outcomes for liver cancer patients through its advanced drug delivery technology and investigational immunotherapy nelitolimod, has entered into a strategic partnership with Geo-Med, LLC, a certified Service-Disabled Veteran-Owned…
Cyrus Biotechnology to Showcase Protein Engineering and IgG Protease at Hit ID Summit
Cyrus Biotechnology, Inc., a Seattle-based biotech company leveraging a novel hybrid AI/screening platform for biologics discovery, will showcase its expertise in protein engineering and risk mitigation for therapeutics at the inaugural Hit ID Summit in Boston. The presentation, scheduled for…
Care Access Brings Free Heart & Kidney Health Screenings to Glendale
Care Access, a global leader in clinical research dedicated to advancing the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Glendale, Arizona. The program aims to raise awareness and offer testing for key health risk…
Almirall Reports Strong Q3 2024 Results Driven by Biologics Growth
Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today reported its financial results for the first nine months of 2024. The company posted strong sales growth, primarily driven by its dermatology business, particularly the biologics portfolio in Europe.…
Oncoinvent Announces Promising Interim Results for Radspherin® in Peritoneal Carcinomatosis Treatment
Oncoinvent ASA, a clinical-stage company developing alpha emitter therapies for solid cancers, today reported interim data from the Phase 1/2a trials of Radspherin® for the treatment of peritoneal carcinomatosis. Recruitment for these studies concluded at the end of 2023, with…
Novotech Wins 2024 Clinical Trials Arena Excellence Award for Business Development and Innovation
Novotech, a full-service global contract research organization (CRO), has been honored with multiple awards at the 2024 Clinical Trials Arena Excellence Awards. These prestigious accolades recognize Novotech’s achievements in business development, innovation, and marketing, underscoring the company’s commitment to advancing…
A2 Bio Highlights Tmod™ CAR T-Cell Progress at 2024 SITC Annual Meeting
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing innovative logic-gated cell therapies to selectively target tumor cells while sparing normal cells, today presented updates on its Tmod™ CAR T-cell clinical programs at the 39th Annual Meeting of…
Lindora Celebrates National Nurse Practitioner Week with Special Offers
In recognition of National Nurse Practitioner Week (November 10-16), Lindora is honoring the contributions of nurse practitioners and wellness professionals with a special offer. There are over 385,000 nurse practitioners (NPs) licensed in the U.S., according to the American Association…
Chemed Board Approves $300M Stock Repurchase and 50¢ Quarterly Dividend
Chemed Corporation (NYSE: CHE) today announced that its Board of Directors has authorized an additional $300 million for stock repurchases under the company’s existing share repurchase program. These repurchases will be funded with a mix of cash generated from operations…